Malaria is the world's leading parasitic endemic and the major cause of morbidity and mortality in Côte d'Ivoire. The aim of this study was to firstly analyse, the clinical aspects and secondly evaluate the kit’s performance (NovaLisa® Malaria) against a panel of antigens (AMA1, GLURP, CSP and Schizont Extract) in order to determine the antigen to be used in diagnosing malaria serology in our country. A retrospective study was carried out on patients (345 samples) requesting malaria serological test. The Novalisa® Malaria kit and a panel of antigens (CSP, GLURP, AMA1 and Schizont Extract) were used. ELISA technique was used for the multi-antigen approach and an antigen panel was used to measure the proportion of responders from 28 samples from which 14 were negative and 14 positives for malaria serology. On a total of 345 samples, a positive rate of 92.49 % (319/345) was revealed by the malaria serology tests with a mean concentration of 50.1 NTU, 6.38 % (22/345) of negativity with a mean concentration of 5.96 NTU and 1.16 % (4/345) in the doubtful zone (mean concentration of 16.26 NTU). Indicators for malaria serology request varied and were dominated by splenomegaly (20 %). Mean concentration for prescriptions were high for Cervical Adenopathy with 73.12 NTU. The seroprevalence concerning the antigen panel was 35.72 %, 50 %, 64.28 % and 78.5 % respectively for AMA1, CSP, GLURP and Schizont Extract for negative samples and the proportion of responders was significant (p = 0.003) for schizont extract. The seroprevalence for the 28 samples was 60.7 % for AMA1 and 89.29 % for Schizont Extract. The proportions of responders to CSP (p = 0.008), GLURP (p < 0.001) and schizont extract (p < 0.001) antigens were significantly higher than those of non-responders. GLURP antigen and Schizont Extract could be used for diagnosing malaria serology in Côte d'Ivoire.
Keywords: Malaria, Plasmodium falciparum, antigen, serodiagnosis